Company / Shareholders' Equity
Kura Oncology, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$174.1M
FY2025
5-year range
$174.1M / $506.6M
FY2021-FY2025
Trend
-57.9%
vs FY2024
Sector context
#157 of 213
Health Care
What the data says
At $174M, Kura Oncology, Inc.'s shareholders' equity ranks #157 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $57M in FY2016 to $611M in FY2020.
Based on SEC 10-K filings.
$174M in FY2025 with a 5-year CAGR of -22.2%.
Declined from $397M to $174M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -25.4%
- 5-Year CAGR
- -22.2%
- 10-Year CAGR
- -
Sector benchmark
#157 of 213 in Health CareTop 74% of 213This company $174.1M Sector average $2.5B
▼
-93.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -22.2%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 57.9% year-over-year.
- Ranks #157 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $174.1M | -57.9% |
| FY2024 | $413.6M | +4.1% |
| FY2023 | $397.3M | -5.5% |
| FY2022 | $420.3M | -17.0% |
| FY2021 | $506.6M | -17.1% |
| FY2020 | $610.9M | +179.2% |
| FY2019 | $218.8M | +35.9% |
| FY2018 | $161.0M | +101.6% |
| FY2017 | $79.9M | +40.4% |
| FY2016 | $56.9M | -30.7% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026